AstraZeneca biliary cancer drug hits Phase 3 trial endpoint

AstraZeneca said its Imfinzi drug “significantly” improved overall survival in biliary tract cancer when combined with chemotherapy, according to phase 3 trial results.

The company on Monday said the trial revealed Imfinzi “demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer (BTC)”.

It added that the combination also demonstrated an improvement in progression-free survival and overall response rate.

BTC is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder